1   1.   A method of screening drug candidates comprising:

2   a) providing a cell that expresses an expression profile gene selected from the

3   group consisting of an expression profile gene set forth in Table 1 or Table 2 or fragment

4   thereof;

5   b) adding a drug candidate to said cell; and

6   c) determining the effect of said drug candidate on the expression of said

7   expression profile gene.

1   2. A method according to claim 1 wherein said determining comprises

2   comparing the level of expression in the absence of said drug candidate to the level of

3   expression in the presence of said drug candidate.

1   3.   A method of screening for a bioactive agent capable of binding to a

2   colorectal cancer modulator protein (colorectal cancer modulator protein), wherein said

3   colorectal cancer modulator protein is encoded by a nucleic acid selected from the group

4   consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof, said method

5   comprising:

6   a) combining said colorectal cancer modulator protein and a candidate

7   bioactive agent; and

8   b) determining the binding of said candidate agent to said colorectal cancer

9   modulator protein.

1   4. A method for screening for a bioactive agent capable of modulating the

2   activity of a colorectal cancer modulator protein, wherein said colorectal cancer modulator

3   protein is encoded by a nucleic acid selected from the group consisting of a nucleic acid of

4   Table 1 or Table 2 or a fragment thereof, said method comprising:

5   a) combining said colorectal cancer modulator protein and a candidate

6   bioactive agent; and

98

7   b) determining the effect of said candidate agent on the bioactivity of said

8   colorectal cancer modulator protein.

1   5. A method of evaluating the effect of a candidate colorectal cancer drug

2   comprising:

3   a) administering said drug to a patient;

4   b) removing a cell sample from said patient; and

5   c) determining the expression of a gene selected from the group consisting of a

6   nucleic acid of Table 1 or Table 2.

1   6. A method according to claim 5 further comprising comparing said

2   expression profile to an expression profile of a healthy individual.

1   7. A method of diagnosing colorectal cancer comprising:

2   a) determining the expression of one or more genes selected from the group

3   consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof or a polypeptide

4   encoded thereby in a first tissue type of a first individual; and

5   b) comparing said expression of said gene(s) from a second normal tissue type

6   from said first individual or a second unaffected individual;

7   wherein a difference in said expression indicates that the first individual has

8   colorectal cancer.

1   8. A method for screening for a bioactive agent capable of interfering with the

2   binding of a colorectal cancer modulator protein (colorectal cancer modulator protein) or a

3   fragment thereof and an antibody which binds to said colorectal cancer modulator protein or

4   fragment thereof, said method comprising:

5   a) combining a colorectal cancer modulator protein or fragment thereof, a

6   candidate bioactive agent and an antibody which binds to said colorectal cancer modulator

7   protein or fragment thereof; and

8   b) determining the binding of said colorectal cancer modulator protein or

9   fragment thereof and said antibody.

1   9. A method for inhibiting the activity of a colorectal cancer modulator
2 protein (colorectal cancer modulator protein), wherein said colorectal cancer modulator
3 protein is encoded by a nucleic acid selected from the group consisting of a nucleic acid of
4 Table 1 or Table 2 or a fragment thereof, said method comprising binding an inhibitor to said
5 colorectal cancer modulator protein.

1   10. A method according to claim 9 wherein said inhibitor is an antibody.

1   11. A method of treating colorectal cancer comprising administering to a
2 patient an inhibitor of a colorectal cancer modulator protein, wherein said colorectal cancer
3 modulator protein is encoded by a nucleic acid selected from the group consisting of a
4 nucleic acid of Table 1 or Table 2 or a fragment thereof.

1   12. A method according to claim 11 wherein said inhibitor is an antibody.

1   13. A method of neutralizing the effect of a colorectal cancer modulator
2 protein, or a fragment thereof, comprising contacting an agent specific for said protein with
3 said protein in an amount sufficient to effect neutralization.

1   14. A method for localizing a therapeutic moiety to colorectal cancer tissue
2 comprising exposing said tissue to an antibody to a colorectal cancer modulator protein or
3 fragment thereof conjugated to said therapeutic moiety.

1   15. The method of Claim 14, wherein said therapeutic moiety is a cytotoxic
2 agent.

1   16. The method of Claim 14, wherein said therapeutic moiety is a
2 radioisotope.

1   17. A method for inhibiting colorectal cancer in a cell, wherein said method
2 comprises administering to a cell a composition comprising antisense molecules to a nucleic
3 acid of Table 1 or Table 2.

1   18. An antibody which specifically binds to a protein encoded by a nucleic
2 acid of Table 1 or Table 2 or a fragment thereof.

1   19. The antibody of Claim 18, wherein said antibody is a monoclonal

2   antibody.

1   20. The antibody of Claim 18, wherein said antibody is a humanized

2   antibody.

1   21. The antibody of Claim 18, wherein said antibody is an antibody fragment.

1   22. A biochip comprising one or more nucleic acid segments selected from

2   the group consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof, wherein

3   said biochip comprises fewer than 1000 nucleic acid probes.

1   23. A nucleic acid having a sequence at least 95% homologous to a sequence

2   of a nucleic acid of Table 1 or Table 2 or its complement.

1   24. A nucleic acid which hybridizes under high stringency to a nucleic acid of

2   Table 1 or Table 2 or its complement.

1   25. A polypeptide encoded by the nucleic acid of Claim 23 or 24.

1   26. A method of eliciting an immune response in an individual, said method

2   comprising administering to said individual a composition comprising the polypeptide of

3   Claim 25 or a fragment thereof.

1   27. A method of eliciting an immune response in an individual, said method

2   comprising administering to said individual a composition comprising a nucleic acid

3   comprising a sequence of a nucleic acid of Table 1 or Table 2 or a fragment thereof.

1   28. A method of determining the prognosis of an individual with colorectal

2   cancer comprising:

3   a) determining the expression of one or more genes selected from the group

4   consisting of a nucleic acid of Table 1 or Table 2 or a fragment thereof in a first tissue type of

5   a first individual; and

6   b) comparing said expression of said gene(s) from a second normal tissue type

7   from said first individual or a second unaffected individual;

8   wherein a substantial difference in said expression indicates a poor prognosis.

1   29. A method of treating colorectal cancer comprising administering to an

2 individual having colorectal cancer an antibody to a colorectal cancer modulator protein or

3 fragment thereof conjugated to a therapeutic moiety.

1   30. The method of Claim 29, wherein said therapeutic moiety is a cytotoxic

2 agent.

1   31. The method of Claim 29, wherein said therapeutic moiety is a

2 radioisotope.